ClinicalTrials.gg
CompletedNCT01137968Updated Jan 26, 2016

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of imetelstat and Bevacizumab in Non-small Cell Lung Cancer, sponsored by Geron Corporation. Completed at 33 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-26.

Sponsored by Geron Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
967th of 2,995
116 · median 56
Started
2010
with 81 others
Phase 2
1,078 of 3,368
119 open now
Registered
1,050th of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 967th largest by enrollment of the 2,995 interventional ones that give a count, is one of 82 that started in 2010, is one of 1,078 in phase 2, and was the 1,050th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

The purpose of this is to evaluate the efficacy and safety of imetelstat (GRN163L) as maintenance therapy for patients with advanced stage NSCLC who have not progressed after 4 cycles of platinum based therapy.

Participants will be randomized in a 2:1 ratio to imetelstat + standard of care versus standard of care alone. Participants who received bevacizumab with their induction chemotherapy will continue to receive bevacizumab on this study.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • imetelstat
  • imetelstat sodium
  • GRN163L
  • telomerase inhibitor
  • telomerase inhibition
  • maintenance therapy
  • non-small cell lung cancer
  • relapsed non-small cell lung cancer
  • advanced non-small cell lung cancer
  • NSCLC, cancer stem cells
  • Bevacizumab
  • post induction chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed .
  • Ability and willingness to comply with requirements of the study protocol.
  • Male or female, age 18 or over.
  • or cytologically confirmed diagnosis of NSCLC
  • Stage IV (using the 7th edition of AJCC, or wet IIIb / IV using the 6th edition), or recurrent locally advanced disease not amenable to radiation or surgery with curative intent and not amenable to concurrent chemoradiation.
  • Patients have completed four to six cycles of platinum-based chemotherapy doublet for , advanced NSCLC, with no evidence of disease progression according to version 1.1. chemotherapy greater than one year prior to progression is allowed.
  • Patients are willing and able to continue treatment with bevacizumab, if they received it with their platinum based chemotherapy.
  • performance status 0-1
  • Adequate bone marrow reserve as measured by ≥ 1500/mm3,

    ≥ 9 g/dL, count ≥ 75,000 μL. Must be measured ≥ 1 week after last transfusion of blood products and/or last dose of hematopoietic growth factor.

  • (PT) or INR or aPTT ≤ 1.5 x .
  • Serum creatinine \< 1.5 mg/dL or > 45 mL/min.
  • Urinalysis with \< 2+ protein or urinary excretion of \< 2 g of protein/day (for patients to receive bevacizumab).
  • (SGOT) and ALT (SGPT) \< 2.5 x the ULN, (AST (SGOT) and ALT (SGPT) \< 5 x the ULN if documented liver ).
  • Serum \< 2.0 mg/dL (patients with Gilbert's syndrome: serum bilirubin \< 3 x ULN).
  • Alkaline phosphatase \< 2.5 x ULN (patients with documented liver or bone metastases, alkaline phosphatase ≤ 5 x ULN).
  • No other obvious related major organ toxicities which would compromise the patient's ability to participate in a clinical trial of a novel agent.
  • Patients may have received prior radiation therapy for local or locally advanced disease providing that any adverse effects associated with prior therapy have recovered to Grade 1 or less.
  • Women of must have a negative serum pregnancy test and agree to use effective during and for 12 weeks after the last treatment with imetelstat.
  • Males must agree to use effective birth control for themselves or their partner during and for 12 weeks after the last treatment with imetelstat.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from screening and study entry:

  • Patients who are not eligible for induction therapy with a platinum based chemotherapy doublet.
  • Patients who have received, or are scheduled to receive pemetrexed or erlotinib as maintenance therapy.
  • Patients receiving bevacizumab must not have a recent history of hemoptysis ≥ ½ teaspoon of red blood or history of ≥ 2 g/24 hr urine protein while receiving prior bevacizumab, or squamous cell histology.

Patients will be excluded from being randomized if any of the following criteria apply:

  • Last dose of induction chemotherapy \< 21 days prior to randomization or > 42 days prior to randomization
  • History of pulmonary hemorrhage (> 1 teaspoon) within the 4 weeks prior to randomization.
  • Anti- therapy within 2 weeks prior to randomization, other than low dose aspirin prophylaxis therapy.
  • Therapeutic anticoagulation therapy except for low dose warfarin (e.g., 1 mg by mouth per day).
  • Radiation therapy within 3 weeks prior to randomization (palliative radiation therapy is allowed, provided that sites of bone marrow production, i.e. iliac crests are not in the radiation field)
  • Major surgery within 4 weeks prior to first study drug administration (central line placement is allowed)
  • Active central nervous system (CNS) disease. Patients with stable CNS disease following completion of radiation therapy and/or surgery are eligible.
  • Any other active
  • Active or chronically recurrent bleeding (e.g., active peptic ulcer disease)
  • infection
  • Active disease requiring therapy
  • Clinically significant cardiovascular disease or condition including:
  • Congestive heart failure (CHF) requiring therapy
  • Need for anti-arrhythmic therapy for a ventricular arrhythmia
  • Severe conduction disturbance
  • Angina pectoris requiring therapy
  • Medically uncontrolled hypertension per the Investigator's discretion
  • Myocardial infarction within 6 months prior to first study drug administration
  • Class II, III, or IV cardiovascular disease
  • Any other severe, acute, or chronic medical or psychiatric condition, laboratory abnormality, or difficulty complying with protocol requirements that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for the study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    imetelstat plus standard of care

    imetelstat plus standard of care (bevacizumab or observation)

    Drug: imetelstat · Drug: Bevacizumab

  • Other
    Standard of care

    Bevacizumab or observation

    Drug: Bevacizumab

Interventions

  • 9.4 mg/kg over a 2 hour IV infusion on Day 1 and Day 8 of each 21 day cycle until disease progression.

    Also known as: GRN163L

  • Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    Defined as the time from randomization to documented disease progression or death, whichever occurs earlier,as determined by the Investigator's assessment according to RECIST, or death from any cause, whichever occurs earlier.

    Time frame: From randomization to documented disease progression or death, whichever occurs earlier, through the end of the study period (8 mos. after the last participant is randomized)

Secondary outcomes

  1. Objective response

    Objective response (partial response plus complete response) occurring post-randomization as determined by the Investigator's assessment according to RECIST criteria using post-induction tumor dimensions as a baseline.

    Time frame: Occurring post randomization through end of study period (8 mos. after the last participant is randomized)

  2. Time to all-cause mortality

    Defined as the time from the date of radomization to death from any cause during the study period.

    Time frame: From the date of randomization through end of study period (8 mos. after the last participant is randomized)

  3. Safety and tolerability

    Safety and tolerability will be assessed by the incidence, nature, and severity of adverse events, laboratory abnormalities, and vital signs.

    Time frame: From the date of randomization through the end of the study period (8 mos. after the last participant is randomized)

07

Study locations

33 sites
  • Achieve Clinical Research, Llc
    Birmingham, Alabama 35216, United States
  • Clearview Cancer Institute
    Huntsville, Alabama 35805, United States
  • Pacific Cancer Medical Center, Inc.
    Anaheim, California 92801, United States
  • Cancer Care Associates of Fresno Medical Group Inc
    Fresno, California 93720, United States
  • St. Joseph's Hospital
    Orange, California 92868, United States
  • Kaiser Permanente Medical Center
    Vallejo, California 94589, United States
  • University of Colorado Denver School of Medicine
    Aurora, Colorado 80045, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Integrated Community Oncology Network
    Jacksonville, Florida 32256, United States
  • H. Moffitt Lee Cancer Center
    Tampa, Florida 33612, United States
  • Ingalls Memorial Hospital
    Harvey, Illinois 60426, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Montgomery Cancer Center
    Mt. Sterling, Kentucky 40353, United States
  • Auerbach Hematology Oncology
    Baltimore, Maryland 21237, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Hematology Oncology Centers
    Billings, Montana 59101, United States
  • Blumenthal Cancer Center
    Charlotte, North Carolina 28204, United States
  • Kaiser Northwest
    Portland, Oregon 97227, United States
  • South Carolina Oncology Associates
    Columbia, South Carolina 29210, United States
  • The Jones Clinic
    Germantown, Tennessee 38138, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Scott and White Memorial Hospital (Texas A & M)
    Temple, Texas 76508, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Hôpital Charles Lemoyne
    Greenfield Park, Quebec J4V 2H1, Canada
  • Hospital Notre-Dame
    Montreal, Quebec H2L 4M1, Canada
  • Krankenhaus Grosshansdorf
    Grosshansdorf, Hamburg 22927, Germany
  • Asklepios Klinik Gauting GmbH
    Gauting, Munich 82131, Germany
  • Klinikum rechts der Isar der TU München
    Munchen, Munich, Germany
  • Krankenhaus Nordwest
    Frankfurt, 60488, Germany
  • Universitaetsklinikum Mainz
    Mainz, 55131, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2010
First posted
Jun 7, 2010
Start
May 2010
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results delay requested
Mar 13, 2015
Last update
Jan 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01137968
Lead sponsor
Geron Corporation
Responsible party
Sponsor
First posted
Jun 7, 2010
Start date
May 2010
Primary completion
Sep 2013
Completion
Sep 2013
Last update
Jan 26, 2016

Study contacts

Joan Schiller, MD
principal investigator · University of Texas

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imetelstat

Start the discussion